Tolerability of ALK Grass Tablet in Children

ALK-Abelló A/S32 enrolled

Overview

The purpose of this trial is to assess whether the ALK Grass tablet treatment is safe to use in children aged 5-12 years

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Masking

DOUBLE

Enrollment

Conditions

Allergy

Interventions

ALK Grass tabletBIOLOGICAL

Eligibility

Sex: ALLMin age: 5 YearsMax age: 12 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Grass pollen induced rhinoconjunctivitis * Boys and girls, 5-12 years of age * Positive skin prick test to grass pollen Exclusion Criteria: * Severe asthma * Previous treatment with immunotherapy

Locations (1)

Servicio de Alergia, Hospital del Niño Jesús

Madrid, Spain

Outcomes

Primary Outcomes

Assessment of safety by recording of adverse events

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.